



Richard Byrd Pollard, M.D.

Philosophy of Care	My philosophy of care is comprehensive primary care of HIV-infected patients and patients with other infectious diseases.
Clinical Interests	Dr. Pollard's clinical research includes usage of new antiviral drugs, the care of HIV-infected patients, HIV vaccines as well as clinical immunology. Pollard's research interests include immunology of viral infections, immune responses to HIV, CMV, HPV, and VZV as well as immunologic non-responders.
Title	Professor
Specialty	Infectious Diseases, Internal Medicine
Department	Internal Medicine
Division	Infectious Diseases
Center/Program Affiliation	Northern California Center for AIDS Research
Address/Phone	CARES Clinic, 1500 21st St. Sacramento, CA 95817 Phone: 800-2-UCDAVIS Patient Support Services Building, 4150 V Street Suite G500 Sacramento, CA 95817
Additional Phone	Phone: 916-734-3815 Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Education	M.D., University of Maryland School of Medicine, Baltimore, Maryland, 1970
Internships	Ohio State University, Columbus, Ohio, 1970-71
Residency	Emory University, Atlanta, Georgia, 1973-75
Fellowships	Stanford University Medical Center, Stanford, California, 1975-78
Board Certifications	American Board of Internal Medicine, 1975
Professional Memberships	American Association of Immunologists American College of Physicians, Fellow Infectious Diseases Society of America, Fellow Sigma Xi



Richard Byrd Pollard, M.D.

Honors and Awards

Best Doctors in America, 2010
Best Doctors in America, 2009
Best Doctors in America, 2007

Select Recent Publications

Rodriguez B, Asmuth DM, Matining RM, Spritzler J, Jacobson JM, Mailliard RB, Li XD, Martinez AI, Tenorio AR, Lori F, Lisiewicz J, Yesmin S, Rinaldo CR, and Pollard RB. Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial. *JAIDS*, 2013;64(4): 351-359.

Nagy LH, Grishina I, Macal M, Hirao LA, Hu WK, Sankaran- Walters S, Gaulke CA, Pollard RB, Brown J, Suni M, Baumler AJ, Ghanekar S, Marco ML, Dandekar S. Chronic HIV infection enhances the responsiveness of antigen presenting cells to commensal lactobacillus. *PLoS ONE*, 2013;8(8): e72789.

Kalayjian RC, Spritzler J, Matining RM, Fiscus SA, Gross BH, Francis IR, Pollard RB, Lederman MM, and Landay A. Older HIVinfected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction. *AIDS*, 2013; 27(10): 1563-1571.

Enkhmaa B, Anuurad E, Zhang W, Abbuthalha A, Li XD, Dotterweich W, Pollard RB, Asmuth DM, Berglund L. HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein (a) levels. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 2013;33(2): 387-392.

Allen ME, Brown J, Karakas SE, and Pollard RB. Refractory AIDS cholangiopathy: metabolic complications and the role of plasmapheresis. *AIDS*, 2013;27(7): 1193–1194.

Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, Pollard RB, Somsouk M, Deeks S, Shacklett BL. HIV+ Viremic Slow Progressors Maintain Low Regulatory T-Cell Numbers in Rectal



Richard Byrd Pollard, M.D.

Mucosa but Exhibit High T-cell Activation. *AIDS Research and Human Retroviruses*, 2013;29(1): 172-177.

Hulgan t, Robbins GK, Kalams SA, Samuels DC, Grady B, Shafer R, Murdock DG, Selph D, Haas DW, Pollard RB for the AIDS Clinical Trials Group. T Cell Activation Markers and African Mitochondrial DNA Haplogroups among Non-Hispanic Black Participants in AIDS Clinical Trials Group Study 384. *PLoS One*, 2012;7(8): e43803.

Hayes TL, Asmuth DM, Critchfield JW, Knight TH, McLaughlin BE, Yotter T, McConnell DH, Garcia JC, Pollard RB, Shacklett BL. Impact of highly active antiretroviral therapy initiation on CD4+ T-cell repopulation in duodenal and rectal mucosa. *AIDS*, 2012;27: 867-877.

Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, Garcia F, Ellefsen K, Podzamczar D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy WD, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, Sommerfelt MA, Wendel-Hansen V, and Sørensen B. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. *The Lancet*, 2014;14(4):291-300.

Brown J, Burger H, Weiser B, Pollard RB, Li XD, Clancy LJ, Baumann R, Rogers A, Hamdan HB, Pesana RL, and Kagan RM. A genotypic HIV-1 proviral DNA coreceptor tropism assay: characterization in viremic subjects. *AIDS Research and Therapy*, 2014;11(14): 1-7.

© 2017 UC Regents